Join Growin Stock Community!

Arrowhead pharmaceuticals, inc.ARWR.US Overview

US StockHealthcare
(No presentation for ARWR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ARWR AI Insights

ARWR Overall Performance

ARWR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ARWR Recent Performance

-1.58%

Arrowhead pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ARWR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ARWR Key Information

ARWR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ARWR Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Price of ARWR

ARWR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ARWR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.44
PE Ratio (TTM)
39.54
Forward PE
-
PS Ratio (TTM)
8.12
PB Ratio
15.61
Price-to-FCF
27.08
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
18.54%
Revenue Growth (YoY)
43539.24%
Profit Growth (YoY)
43539.24%
3-Year Revenue Growth
61.62%
3-Year Profit Growth
61.62%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.44
PE Ratio (TTM)
39.54
Forward PE
-
PS Ratio (TTM)
8.12
PB Ratio
15.61
Price-to-FCF
27.08
Gross Margin
100.00%
Net Margin
18.54%
Revenue Growth (YoY)
43539.24%
Profit Growth (YoY)
43539.24%
3-Year Revenue Growth
61.62%
3-Year Profit Growth
61.62%

  • When is ARWR's latest earnings report released?

    The most recent financial report for Arrowhead pharmaceuticals, inc. (ARWR) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ARWR's short-term business performance and financial health. For the latest updates on ARWR's earnings releases, visit this page regularly.

  • Where does ARWR fall in the P/E River chart?

    According to historical valuation range analysis, Arrowhead pharmaceuticals, inc. (ARWR)'s current price-to-earnings (P/E) ratio is 44.75, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ARWR?

    According to the latest financial report, Arrowhead pharmaceuticals, inc. (ARWR) reported an Operating Profit of 40.81M with an Operating Margin of 15.46% this period, representing a growth of 125.28% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ARWR's revenue growth?

    In the latest financial report, Arrowhead pharmaceuticals, inc. (ARWR) announced revenue of 264.03M, with a Year-Over-Year growth rate of 10,461.32%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ARWR have?

    As of the end of the reporting period, Arrowhead pharmaceuticals, inc. (ARWR) had total debt of 687.76M, with a debt ratio of 0.43. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ARWR have?

    At the end of the period, Arrowhead pharmaceuticals, inc. (ARWR) held Total Cash and Cash Equivalents of 201.64M, accounting for 0.13 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ARWR go with three margins increasing?

    In the latest report, Arrowhead pharmaceuticals, inc. (ARWR) achieved the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of 15.46%%, and net margin of 11.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ARWR's profit trajectory and future growth potential.

  • Is ARWR's EPS continuing to grow?

    According to the past four quarterly reports, Arrowhead pharmaceuticals, inc. (ARWR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ARWR?

    Arrowhead pharmaceuticals, inc. (ARWR)'s Free Cash Flow (FCF) for the period is 11.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 107.37% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ARWR?

    The latest valuation data shows Arrowhead pharmaceuticals, inc. (ARWR) has a Price-To-Earnings (PE) ratio of 44.75 and a Price/Earnings-To-Growth (PEG) ratio of -0.33. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.